Aura Biosciences, Inc.

Aura Biosciences, Inc. (AURA) priced its initial public offering on Nov 1, 2021 at $14.00 per share, within its $14.00–$16.00 range, raising $75.6M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $397.7M. Goodwin Procter advised the company and Cooley advised the underwriters.

Aura Biosciences, Inc. is a clinical-stage biotechnology company developing targeted cancer therapies on a platform of virus-like drug conjugates. It focuses initially on ocular and urologic oncology, using virus-like particles that recognize a surface marker found on many solid tumors.

Status

IPO

Ticker

AURA

Exchange

Nasdaq Global Market

Priced

Nov 1, 2021

IPO price

$14.00

Price range

$14.00–$16.00

Raised

$75.6M

Market cap at IPO price

$397.7M

First filed

Oct 8, 2021

Company counsel

Goodwin Procter

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.